中西医结合在原发性肝癌临床治疗中的应用价值分析

Analysis of Combination of TCM and Western Medicine in the Treatment of Hepatocellular Carcinoma

目的：探讨中西医结合应用治疗原发性肝癌的临床效果。方法：2007年1月～2010年1月在我院诊治的原发性肝癌患者154例，随机分为观察组（77例）和对照组（77例），观察组患者在介入化疗栓塞治疗基础上行中医治疗，对照组患者进行介入化疗栓塞治疗。结果：观察组患者治疗有效率59.74%，对照组治疗有效率58.44%；患者胃肠道反应发生率、白细胞降低发生率、行为稳定率、生存期观察组分别为：37.66%、48.05%、64.93%、（5.12±3.27）月，对照组分别为：63.64%、70.13%、59.74%、（4.97±2.95）月。结论：中西医结合治疗能够减少介入化疗栓塞治疗原发性肝癌的不良反应，提高患者生活质量，但未改善患者临床疗效和生存期。

Objective： To investigate the primary liver cancer treatment clinical effect of Integrative Medicine applications. Methods：154 cases of primary liver cancer patients in our hospital January 2007 to January 2010, Were randomly divided into observation group （77 cases） and control group （77 cases）, the patients in the interventional chemoembolization based on the uplink Chinese medicine treatment, the control group patients with interventional chemoembolization therapy. Results： The patients efficiency of 59.74%, the control group was 58.44%; Patients with gastrointestinal reactions incidence of leukopenia incidence of behavioral stability rate, the lifetime of the observation group were： 37.66%, 48.05%, 64.93%, （5.12±3.27） months, the control group were： 63.64%, 70.13%59.74% （4.97±2.95） months. Conclusion： Integrative Medicine can reduce the interventional chemoembolization treatment of primary liver adverse reactions,Improve the quality of life of patients, but did not improve clinical response and survival.